Uricosuric therapy and urate solubility in blood and urine.
In most patients with primary gout hyperuricaemia results from a renal defect in tubular uric acid secretion. An increased endogenous purine biosynthesis is observed in only 2% of all patients with gout. Secondary hyperuricaemai results either from an increased breakdown of endogenous nucleic acids as in polycythaemia or from a decreased renal excretion of uric acid due to drug treatment, renal insufficiency or metabolic disturbances. Hyperuricaemia may be defined either in statistical terms from epidemiological studies of normal and gouty populations or from physicochemical properties of urate. Monosodium urate and uric acid are soluble in water to the extent of 6.32 mmol/l and 0.39 mmol/l respectively. In human plasma saturation of monosodium urate occurs at a concentration of about 0.42 mmol/l. The solubility of uric acid and urate in urine is more complicated as it is affected by changes in pH and salt concentration. Uricosuric drugs decrease serum uric acid concentration by enhancing the renal excretion of uric acid. Effects and side effects of uricosuric therapy are discussed.
D006073:Gout / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D012995:Solubility; D014527:Uric Acid / Q000097:blood / Q000378:metabolism* / Q000652:urine; D014528:Uricosuric Agents / Q000009:adverse effects / Q000627:therapeutic use*
D014528:Uricosuric Agents; D014527:Uric Acid